Emerging corticosteroid delivery platforms for treatment of diabetic macular edema.

Emerging corticosteroid delivery platforms for treatment of diabetic macular edema. Expert Opin Emerg Drugs. 2020 Aug 20;: Authors: Shah JN, Vaze A, Tang Lee Say T, Gillies MC, Fraser-Bell S Abstract INTRODUCTION: Diabetic macular edema (DME) is a leading cause of vision impairment. Low-grade inflammation is thought to play a critical role in its pathogenesis. Although vascular endothelial growth factor inhibitors are used first-line, not all eyes with DME respond optimally and may respond better to corticosteroids. Currently corticosteroids for DME are given intravitreally and require regular monitoring. There is an unmet need for longer lasting therapies and/or effective non-invasive therapies such as those given via oral or topical routes. AREAS COVERED: This review discusses emerging corticosteroid agonists for the treatment of DME. A literature search of investigational novel therapeutic steroid delivery platform in DME was conducted. Results are presented from preclinical, phase 1,2 & 3 clinical trials of various drug delivery systems using new technologies such as Solubilizing Nanoparticle technology, Mucus Penetrating Particles technology and Particle Replication In Non-wetting Templates. These new platforms aim to deliver corticosteroids effectively via topical, episcleral, subtenon, oral and intravitreal routes. EXPERT OPINION: These novel drug delivery platforms have the potential to lead to non-invasiv...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research